Literature DB >> 25617517

[Three types of brand name loyalty strategies set up by drug manufacturers].

Marie-Claude PréMont1, Marc-André Gagnon2.   

Abstract

The recent restructuring of the pharmaceutical industry has led to three new types of promotional strategies to build patient loyalty to brand name drugs: loyalty through rebates, patient support, and compassion programs. Loyalty through rebates seeks to keep patients on a brand name drug and prevent their switch to the generic equivalent. Loyalty through patient support provides aftersales services to help and support patients (by phone or home visits) in order to improve adherence to their treatments. Finally, compassion programs offer patients access to drugs still awaiting regulatory approval or reimbursement by insurers. When and if the approval process is successful, the manufacturer puts an end to the compassion program and benefits from a significant cohort of patients already taking a very expensive drug for which reimbursement is assured. The impact of these programs on public policies and patients' rights raises numerous concerns, among which the direct access to patients and their health information by drug manufacturers and upward pressure on costs for drug insurance plans.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25617517      PMCID: PMC4748359     

Source DB:  PubMed          Journal:  Healthc Policy        ISSN: 1715-6572


  8 in total

1.  Generic atorvastatin and health care costs.

Authors:  Cynthia A Jackevicius; Mindy M Chou; Joseph S Ross; Nilay D Shah; Harlan M Krumholz
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  The cost of drug coupons.

Authors:  David Grande
Journal:  JAMA       Date:  2012-06-13       Impact factor: 56.272

3.  Medication access through patient assistance programs.

Authors:  Danielle Chauncey; C Daniel Mullins; Bac V Tran; Diane McNally; Robert N McEwan
Journal:  Am J Health Syst Pharm       Date:  2006-07-01       Impact factor: 2.637

4.  Prescription-drug coupons--no such thing as a free lunch.

Authors:  Joseph S Ross; Aaron S Kesselheim
Journal:  N Engl J Med       Date:  2013-08-28       Impact factor: 91.245

Review 5.  What is the evidence for pharmaceutical patient assistance programs? A systematic review.

Authors:  Tisha M Felder; Nynikka R Palmer; Lincy S Lal; Patricia Dolan Mullen
Journal:  J Health Care Poor Underserved       Date:  2011-02

6.  Pharmaceutical manufacturer assistance programs.

Authors:  Marie A Chisholm; Joseph T DiPiro
Journal:  Arch Intern Med       Date:  2002-04-08

7.  Drug company-sponsored patient assistance programs: a viable safety net?

Authors:  Niteesh K Choudhry; Joy L Lee; Jessica Agnew-Blais; Colleen Corcoran; William H Shrank
Journal:  Health Aff (Millwood)       Date:  2009 May-Jun       Impact factor: 6.301

8.  The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States.

Authors:  Marc-André Gagnon; Joel Lexchin
Journal:  PLoS Med       Date:  2008-01-03       Impact factor: 11.069

  8 in total
  2 in total

1.  Co-pay cards in Canada: Improving choice or institutionalizing bribes?

Authors:  Marc-André Gagnon
Journal:  CMAJ       Date:  2019-11-11       Impact factor: 8.262

2.  Impact of brand drug discount cards on private insurer, government and patient expenditures.

Authors:  Michael R Law; Fiona K I Chan; Mark Harrison; Heather C Worthington
Journal:  CMAJ       Date:  2019-11-11       Impact factor: 8.262

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.